Dr. Michelle Aszterbaum, MD

Dr. Aszterbaum practices at Beth Ary MD Inc in Newport Beach, California.

Dr. Aszterbaum's NPI, 1992891329, was assigned on October 5, 2006. Dr. Aszterbaum graduated from UC Davis School of Medicine in 1993. Dr. Aszterbaum holds California license G81356.

Dr. Aszterbaum's primary practice is Beth Ary MD Inc, at 1441 Avocado Ave, Newport Beach, CA 92660 in Orange County. The practice phone is (949) 640-7200.

Dr. Aszterbaum's primary practice is Beth Ary MD Inc in Newport Beach, California. Dr. Aszterbaum is also affiliated with Hoag Hospital Newport Beach. The medical group on file is Skin Cancer and Reconstructive Surgery (SCARS) Center. Dmand AI also links Dr. Aszterbaum to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aszterbaum practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Aszterbaum's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Aszterbaum is board certified in dermatology by the American Board of Dermatology. Dr. Aszterbaum is licensed in California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and hives among the conditions Dr. Aszterbaum treats.

CMS data shows 8,927 Medicare services from Dr. Aszterbaum across 33 procedure codes in 2024, for 721 Medicare patients. Medicare paid $362,306 for them. Every service was in an office.

CMS counts 721 Medicare patients who saw Dr. Aszterbaum in 2024. The largest group is 75 to 84, with 327 patients. 75% of them have high cholesterol, and 61% have high blood pressure. Their average risk score is 0.87, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Aszterbaum's median patient age at 63, with 61% women.

In 2024, Dr. Aszterbaum wrote 709 Medicare Part D claims for 273 patients. 91% of them were for generic drugs. CMS names the drug for 571 of them, across 20 drugs with 11 or more claims each, at $113,032 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Aszterbaum for performance year 2024, reported through an alternative payment model (APM). Dr. Aszterbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 2,374 procedures of removal of skin lesions by Dr. Aszterbaum, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 15 papers to Dr. Aszterbaum, published from 2014 to 2016. The most frequent topics are Skin Neoplasms, Carcinoma, Basal Cell and Basal Cell Nevus Syndrome. Dr. Aszterbaum has published most often in J Invest Dermatol. Dr. Aszterbaum's most frequent co-authors are Ervin Epstein, MD, David R. Bickers, MD and Anita Morena Chanana, MD.

CMS Open Payments shows 63 general payments to Dr. Aszterbaum from 17 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Incyte Corporation paid the most, $300.

Dmand AI lists 2 awards for Dr. Aszterbaum.

Dr. Aszterbaum graduated from UC Davis School of Medicine in 1993. Dr. Aszterbaum is a member of AAD.

Dr. Aszterbaum is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.